LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Holiday book sale: Save up to 30% on print and eBooks. No promo code needed.
Save up to 30% on print and eBooks.
Polymer-Protein Conjugates
From Pegylation and Beyond
1st Edition - October 30, 2019
Editors: Gianfranco Pasut, Samuel Zalipsky
Paperback ISBN:
9 7 8 - 0 - 4 4 4 - 6 4 0 8 1 - 9
eBook ISBN:
9 7 8 - 0 - 4 4 4 - 6 4 0 8 2 - 6
Polymer–Protein Conjugates: From Pegylation and Beyond helps researchers by offering a unique reference and guide into this fascinating area. Sections cover the challenges… Read more
Purchase options
Polymer–Protein Conjugates: From Pegylation and Beyond helps researchers by offering a unique reference and guide into this fascinating area. Sections cover the challenges surrounding the homogeneity of conjugates, their purity and polymer toxicity on long-term use, and how to deal with the risk of immunogenicity. These discussions help researchers design new projects by taking into account the latest innovations for safe and site selective polymer conjugation to proteins. PEG has been the gold standard and likely will play this role for many years, but alternatives are coming into the market, some of which have already been launched.
After five decades of improvements, the ideas in this book are entering into a new era of innovation because of the advances in genetic engineering, biochemistry and a better understanding of the results from clinical use of PEG conjugates in humans.
- Provides an overview on the state-of-the-art of protein polymer conjugation
- Presents both the pros and cons of polymer-protein conjugates from the point-of-view of their clinical outcomes
- Outlines advantages and potential risks of present technology based on PEG
- Offers new alternatives for PEG and new approaches for on site-selective protein modification
- Identifies future direction of research in this field
Graduate students and advanced researchers from academic/industrial backgrounds who are interested in protein modification and delivery. The potential users can be pharmacologists, who want insight on this technology regarding approved product, as well as a biochemical engineers, who wants to learn how to design future protein conjugates. Probably a chemist would be less involved although chemistry is at the basis of most successful conjugates. Patent attorneys, since PEGylation is described in many patents
Introduction and General Aspects of the Technology
1. Evolution of Polymer Conjugation to proteins
Samuel Zalipsky and Gianfranco Pasut
2. PEGylated Proteins: A Rational Design for Mitigating Clearance Mechanisms and Altering Biodistribution
Maria J. Vicent and Mary Bossard
3. Overcoming barriers for tumor-targeted drug delivery: the power of macromolecular anticancer drugs with the EPR effect and the modulation of vascular physiology
Hiroshi Maeda and Waliul Islam
Toxicity and Immunogenicity Studies and Clinical Stage Conjugate Products
4. PEG-protein conjugates: Non-clinical and clinical toxicity considerations
Peter L. Turecek and Juergen Siekmann
5. Immunological responses to PEGylated proteins: anti-PEG antibodies
Nehal E. Elsadek, Amr S. Abu Lila, and Tatsuhiro Ishida
6. Immunogenicity assessment of PEGylated proteins, Lonquex, a PEGylated G-CSF case study
Steffen Nock and Linglong Zou
7. PEG-Protein conjugates: regulatory requirements for characterization
Mary J. Bossard
8. PEGylation of human coagulation factor VIII and other plasma proteins
Peter L. Turecek and Juergen Siekmann
9. Pegvorhyaluronidase Alfa: A PEGylated Recombinant Human Hyaluronidase PH20 for the Treatment of Cancers That Accumulate Hyaluronan
Daniel C. Maneval, Chris Caster, Celine Derunes, et al.
10. Challenges in the analytical characterization of PEGylated asparaginases
Gunda Brandenburg, Sabine Poppenborg, Christoph Radcke, et al.
Novel Site-Selective Methods of Conjugation
11. Glycan-targeted PEGylation for selective modification of proteins
M. Eugenia Giorgi, Rosalía Agusti and Rosa M. Lederkremer
12. Sialyltransferase mediated glycoPEGylation
Carsten Behrens and Jens Buchardt
13. Enzymatic approaches to new protein conjugates
Antonella Grigoletto, Katia Maso, and Gianfranco Pasut
14. Site-specific Polymer-protein conjugates by Cys mutation
Nandini V. Katre
15. Site-specific PEGylation of interferon beta-1b: from bench to clinic
Natalie Winblade Nairn
16. Protein modification by bis-alkylation
Christina Picken, Sahar Awwad, Mire Zloh, Hanieh Khalili, and Steve Brocchini
Alternative non-PEG polymers and architectures
17. In vivo properties of therapeutic bioconjugates composed of proteins and architecturally/functionally complex polymers
Ahlem Zaghmi, Andrea A Greschner, and Marc A. Gauthier
18. Poly(2-oxazoline)-protein conjugates
Ondrej Sedlacek, Victor R. de la Rosa, and Richard Hoogenboom
19. Polysaccharides for protein and peptide conjugation
Elaine L. Ferguson, Mathieu Varache, Joana Stokniene and David W. Thomas
20. Polysialylation of human coagulation factor VIII
Peter L. Turecek and Juergen Siekmann
- No. of pages: 512
- Language: English
- Published: October 30, 2019
- Imprint: Elsevier
- Paperback ISBN: 9780444640819
- eBook ISBN: 9780444640826
GP
Gianfranco Pasut
Gianfranco Pasut, PhD is Full Professor of Pharmaceutical Technology at the University of Padua and has more than 20 years of research experience in the field of drug and protein delivery, in particular by polymer conjugation. He is an author of more than 70 peer-reviewed publications and 14 book chapters on polymer conjugation and an inventor of 9 patents. His research lab investigates new approaches of polymer conjugation, ADC and targeted liposome preparations and pioneered and expanded the use of the enzyme transglutaminase for the development of new conjugates.
Affiliations and expertise
Head of Pasut’s Protein and Drug Delivery Lab, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padova, ItalySZ
Samuel Zalipsky
Samuel Zalipsky, Ph.D. is currently an independent consultant in the areas of carrier mediated drug delivery, nanoparticles, biocompatible polymers, liposomes, preparation and applications of a wide spectrum of bioconjugates, and PEGylated biopharmaceuticals in particular. His professional tenure of over 30 years was spent mainly in pharmaceutical industry, contributing to several commercialized technologies and products. He is an author of over 90 publications and listed as an inventor on over 50 patents.
Affiliations and expertise
Independent Pharmaceutical Drug Delivery and Biotechnology Consultant